Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HSAQNYSE:INFUNASDAQ:LUCDNASDAQ:OBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHSAQHealth Sciences Acquisitions Co. 2$3.01+0.7%$2.89$9.41▼$13.80$33.75M0.09205,918 shs250,716 shsINFUInfuSystem$6.18-1.1%$5.54$4.61▼$9.97$129.88M1.81101,231 shs160,902 shsLUCDLucid Diagnostics$1.19-5.6%$1.28$0.71▼$1.80$136.32M1.31605,072 shs919,905 shsOBIOOrchestra BioMed$3.10+3.0%$2.90$2.37▼$8.87$115.32M0.64175,541 shs202,057 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHSAQHealth Sciences Acquisitions Co. 20.00%-2.59%+9.85%-33.26%-52.37%INFUInfuSystem0.00%+0.64%+15.53%+2.97%-4.87%LUCDLucid Diagnostics0.00%-2.33%-20.75%-16.00%+81.84%OBIOOrchestra BioMed0.00%-2.59%+10.66%-34.14%-52.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AN/AN/AN/AINFUInfuSystem3.2096 of 5 stars2.03.00.00.03.84.21.9LUCDLucid Diagnostics3.3476 of 5 stars3.65.00.00.02.71.70.6OBIOOrchestra BioMed1.4669 of 5 stars3.63.00.00.00.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHSAQHealth Sciences Acquisitions Co. 2 0.00N/AN/AN/AINFUInfuSystem 4.00Strong Buy$13.00110.36% UpsideLUCDLucid Diagnostics 3.20Buy$3.55198.32% UpsideOBIOOrchestra BioMed 3.20Buy$14.20358.06% UpsideCurrent Analyst Ratings BreakdownLatest HSAQ, LUCD, OBIO, and INFU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.50 ➝ $7.755/15/2025LUCDLucid DiagnosticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$2.00 ➝ $2.005/14/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.005/13/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/5/2025OBIOOrchestra BioMedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $12.004/23/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/22/2025OBIOOrchestra BioMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/21/2025LUCDLucid DiagnosticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.504/11/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.004/4/2025OBIOOrchestra BioMedHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/A($0.62) per shareN/AINFUInfuSystem$137.58M0.94$0.48 per share12.79$2.47 per share2.50LUCDLucid Diagnostics$4.35M29.60N/AN/A($0.78) per share-1.53OBIOOrchestra BioMed$2.64M44.99N/AN/A$0.87 per share3.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHSAQHealth Sciences Acquisitions Co. 2-$380KN/A0.00∞N/AN/AN/A-2.38%N/AINFUInfuSystem$870K$0.14103.0219.94N/A1.12%2.78%1.41%N/ALUCDLucid Diagnostics-$45.53M-$1.34N/AN/AN/A-1,699.86%N/A-124.27%8/11/2025 (Estimated)OBIOOrchestra BioMed-$61.02M-$1.78N/AN/AN/A-2,297.85%-189.26%-93.76%N/ALatest HSAQ, LUCD, OBIO, and INFU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025OBIOOrchestra BioMed-$0.46-$0.49-$0.03-$0.49$0.39 million$0.87 million3/31/2025Q4 2024OBIOOrchestra BioMed-$0.43-$0.43N/A-$0.43$0.79 million$0.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/AOBIOOrchestra BioMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHSAQHealth Sciences Acquisitions Co. 2N/A0.170.61INFUInfuSystem0.501.981.59LUCDLucid DiagnosticsN/A0.750.74OBIOOrchestra BioMed0.853.353.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHSAQHealth Sciences Acquisitions Co. 289.71%INFUInfuSystem71.13%LUCDLucid Diagnostics74.01%OBIOOrchestra BioMed53.55%Insider OwnershipCompanyInsider OwnershipHSAQHealth Sciences Acquisitions Co. 221.90%INFUInfuSystem11.40%LUCDLucid Diagnostics6.80%OBIOOrchestra BioMed8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHSAQHealth Sciences Acquisitions Co. 2411.21 million8.76 millionNot OptionableINFUInfuSystem41021.02 million19.10 millionOptionableLUCDLucid Diagnostics70108.19 million100.83 millionNo DataOBIOOrchestra BioMed438.31 million35.21 millionNot OptionableHSAQ, LUCD, OBIO, and INFU HeadlinesRecent News About These CompaniesOrchestra BioMed Highlights Potential of AVIM Therapy for Managing Hypertension in High-Risk Patients at CSI 2025 MeetingJune 20 at 2:46 PM | nasdaq.comOrchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 MeetingJune 18, 2025 | msn.comOrchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025June 18, 2025 | globenewswire.comOrchestra BioMed: Two Best-In-Class Devices And Promising PartnershipsMay 28, 2025 | seekingalpha.comOrchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative OptimismMay 14, 2025 | seekingalpha.comOrchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comOrchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical MilestonesMay 12, 2025 | globenewswire.comOrchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough DesignationMay 11, 2025 | msn.comOrchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global PatentsMay 9, 2025 | nasdaq.comWhy Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 19.92%May 9, 2025 | aaii.comOrchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart FailureMay 8, 2025 | finance.yahoo.comOrchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart FailureMay 7, 2025 | globenewswire.comOrchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?May 5, 2025 | zacks.comOrchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR TreatmentMay 1, 2025 | msn.comOrchestra BioMed to Present at Jefferies Global Healthcare ConferenceMay 1, 2025 | msn.comWhy Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 7.51%May 1, 2025 | aaii.comFDA approves head-to-head trial of Orchestra BioMed’s balloonApril 30, 2025 | investing.comOrchestra BioMed wins FDA IDE for sirolimus-angioballoonApril 29, 2025 | massdevice.comOrchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated BalloonApril 29, 2025 | globenewswire.comOrchestra BioMed to Participate in Upcoming Institutional Investor ConferencesApril 28, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSAQ, LUCD, OBIO, and INFU Company DescriptionsHealth Sciences Acquisitions Co. 2 NASDAQ:HSAQ$3.01 +0.02 (+0.67%) As of 06/20/2025Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.InfuSystem NYSE:INFU$6.18 -0.07 (-1.12%) Closing price 04:00 PM EasternExtended Trading$6.19 +0.01 (+0.16%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Lucid Diagnostics NASDAQ:LUCD$1.19 -0.07 (-5.56%) Closing price 04:00 PM EasternExtended Trading$1.23 +0.04 (+3.36%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Orchestra BioMed NASDAQ:OBIO$3.10 +0.09 (+2.99%) Closing price 04:00 PM EasternExtended Trading$3.15 +0.05 (+1.61%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
